Pre-made Nipocalimab benchmark antibody ( Whole mAb, anti-FCGRT therapeutic antibody, Anti-FCRN/FcgammaRn/alpha-chain Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-378

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-378 Category Tag

Product Details

Pre-Made Nipocalimab biosimilar, Whole mAb, Anti-FCGRT Antibody: Anti-FCRN/FcgammaRn/alpha-chain therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Nipocalimab is a fully human, aglycosylated, effectorless immunoglobulin G1 (IgG) anti-FcRN antibody that functions to reduce the levels of other IgG antibodies in the blood, including the autoantibodies that cause gMG.

Products Name (INN Index)

Pre-Made Nipocalimab biosimilar, Whole mAb, Anti-FCGRT Antibody: Anti-FCRN/FcgammaRn/alpha-chain therapeutic antibody

INN Name

Nipocalimab

Target

FCGRT

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Lambda

Highest_Clin_Trial (Jan '20)

Phase-III

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

5whk:HL/5whj:HL

Year Proposed

2019

Companies

Momenta

Conditions Approved

NA

Conditions Active

Autoimmune haemolytic anaemia,Haemolytic disease of newborn,Myasthenia gravis

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

FCGRT

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide